Camber Pharmaceuticals Launches Theophylline Extended-Release Tablets
Theophylline Extended-Release Tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases.
Camber Pharmaceuticals is pleased to announce the addition of Theophylline Extended-Release Tablets to its current portfolio.
Theophylline Extended-Release Tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases.
Theophylline Extended-Release Tablets are available in 300 mg and 450 mg strengths, both in 100 count bottles.
To find out more about Theophylline Extended-Release Tablets, please visit https://www.camberpharma.com/theophylline-er
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.
